Compare GMM & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GMM | ENVB |
|---|---|---|
| Founded | 2017 | 1994 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8M | 8.1M |
| IPO Year | 2022 | 2000 |
| Metric | GMM | ENVB |
|---|---|---|
| Price | $2.61 | $1.33 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.8M | 101.4K |
| Earning Date | 01-09-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $39,914,675.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.06 | $0.56 |
| 52 Week High | $5.79 | $13.25 |
| Indicator | GMM | ENVB |
|---|---|---|
| Relative Strength Index (RSI) | 52.20 | 37.56 |
| Support Level | $1.11 | $0.60 |
| Resistance Level | $4.75 | $1.58 |
| Average True Range (ATR) | 0.48 | 0.11 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 22.43 | 23.38 |
Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital asset development for the metaverse industry. The Company leverages its proprietary Mofy Lab technology platform, which integrates three-dimensional (3D) reconstruction technology and artificial intelligence (AI) interactive technology, to create high-definition virtual versions of physical world objects, including humans, animals, and scenes. It provides comprehensive technology solutions to support virtual content production for use across movies, television series, animation, advertising, and gaming. The Company operates through Virtual Technology Services, which generates the majority of revenue, and Digital Asset Development and others.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.